Scarica l'app Stockscreener
30.67
1.22%
0.37
Dopo l'orario di chiusura:
30.68
0.010
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$30.30
Aprire:
$30.32
Volume 24 ore:
1.62M
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.12B
Reddito:
$139.74M
Utile/perdita netta:
$-79.99M
Rapporto P/E:
-30.20
EPS:
-1.0157
Flusso di cassa netto:
$-360.05M
1 W Prestazione:
+20.56%
1M Prestazione:
+21.90%
6M Prestazione:
+12.80%
1 anno Prestazione:
+77.49%
Intervallo 1D:
$29.86
$31.36
Intervallo di 1 settimana:
$25.20
$31.54
Portata 52W:
$15.35
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
30.67 | 3.09B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.85 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Baillie Gifford & Co. Boosts Beam Therapeutics Stake by 40% - National Today
Beam Therapeutics CEO Sells 30,078 Shares in April 2026 Transaction | Stock UpdateNews and Statistics - IndexBox
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - Yahoo Finance
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. - The Motley Fool
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
BEAM Price Today: Beam Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Beam Therapeutics President Sells $290,289 in Stock - National Today
(BEAM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Beam Therapeutics CEO Sells Over $700K in Stock - National Today
BEAM Forecast, Price Target & Analyst Ratings | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Insider Sells $146K in Shares - National Today
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock By Investing.com - Investing.com Australia
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock By Investing.com - Investing.com India
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares of Stock - MarketBeat
John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares - MarketBeat
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock By Investing.com - Investing.com Australia
Beam Therapeutics president sells $290k in shares By Investing.com - Investing.com Australia
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
Amy Simon, Beam Therapeutics CMO, sells $164,686 in stock - Investing.com
Beam Therapeutics president sells $290k in shares - Investing.com
[Form 4] Beam Therapeutics Inc. Insider Trading Activity - Stock Titan
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Beam Therapeutics (BEAM) CMO covers tax obligations via 6,700-share sale - Stock Titan
Beam Therapeutics (BEAM) SVP auto-sells shares to cover RSU tax obligations - Stock Titan
Beam Therapeutics (BEAM) CLO auto-sells 5,956 shares for RSU tax withholding - Stock Titan
Beam Therapeutics (BEAM) president’s 11,810-share sale covers RSU taxes - Stock Titan
Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M. - Moomoo
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
SG Americas Securities LLC Boosts Beam Therapeutics Stake by 139% - National Today
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics Inc. (BEAM) interactive stock chart - sg.finance.yahoo.com
Beam Therapeutics (NASDAQ: BEAM) awards 20,000 RSUs to Chief Legal Officer - Stock Titan
Beam Therapeutics (BEAM) awards 20,000 RSUs to SVP Bethany Cavanagh - Stock Titan
Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon - Stock Titan
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs - Stock Titan
Beam Therapeutics (BEAM) grants president 40,000 restricted stock units - Stock Titan
Beam Therapeutics (BEAM): Among the stocks that could 10x over the next 5 years - MSN
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock - MarketBeat
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years - Yahoo Finance
Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing - Moomoo
Beam Therapeutics shares climb after positive BEAM-302 trial update - MSN
Beam (BEAM) Reports Promising Data from BEACON Trial in Sickle C - GuruFocus
Beam Therapeutics publishes sickle cell therapy trial data By Investing.com - Investing.com Australia
Why Is BEAM Stock Edging Higher After Hours Today? - Stocktwits
Beam Therapeutics CEO Evans sells $1.1m in stock By Investing.com - in.investing.com
Beam Therapeutics CEO Evans sells $1.1m in stock - Investing.com
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beam Therapeutics Inc Azioni (BEAM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
2.43%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):